A myeloma cell line established from a patient refractory to thalidomide therapy revealed high-risk cytogenetic abnormalities and produced vascular endothelial growth factor

Detalles Bibliográficos
Autores principales: Hattori, Y, Du, W, Yamada, T, Ichikawa, D, Matsunami, S, Matsushita, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674455/
https://www.ncbi.nlm.nih.gov/pubmed/23686003
http://dx.doi.org/10.1038/bcj.2013.13

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674455/
https://www.ncbi.nlm.nih.gov/pubmed/23686003
http://dx.doi.org/10.1038/bcj.2013.13

Ejemplares similares